Saima Sharif | Department of Internal ...

Dr. Saima Sharif, MD

Claim this profile

University of Iowa/Holden Comprehensive Cancer Center

Studies Colon Cancer
Studies Colorectal Cancer
10 reported clinical trials
25 drugs studied

Area of expertise

1Colon Cancer
Saima Sharif, MD has run 6 trials for Colon Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Colorectal Cancer
Saima Sharif, MD has run 4 trials for Colorectal Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.
University Of Iowa/Holden Comprehensive Cancer Center
Image of trial facility.
University Of Iowa Healthcare Cancer Services Quad Cities

Clinical Trials Saima Sharif, MD is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Dostarlimab

for Colon Cancer

This trial is testing the immunotherapy drug dostarlimab in patients with Stage II and III colon cancer. The goal is to see if the drug can shrink the tumors enough to avoid surgery. Dostarlimab helps the immune system attack the cancer cells.
Recruiting2 awards Phase 2

More about Saima Sharif, MD

Clinical Trial Related2 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Saima Sharif, MD has experience with
  • Dostarlimab
  • Fluorouracil
  • Leucovorin
  • Irinotecan
  • Leucovorin Calcium
  • Oxaliplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Saima Sharif, MD specialize in?
Is Saima Sharif, MD currently recruiting for clinical trials?
Are there any treatments that Saima Sharif, MD has studied deeply?
What is the best way to schedule an appointment with Saima Sharif, MD?
What is the office address of Saima Sharif, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security